Clinical trials: Warfarin
Healthy
Interaction Between ABT-335, Rosuvastatin and Warfarin
This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
- Trial name
- NCT00487136
- Testing
- Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cancer
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor that is being developed for the treatment of BRAF mutation-positive tumors.
- Trial name
- NCT01340846
- Testing
- Warfarin, Ketoconazole, Gemfibrozil
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Healthy
Determinants of Warfarin Metabolism
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.
- Trial name
- NCT00162474
- Testing
- Warfarin, Phenytoin, Losartan & Hydrochlorothiazide
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Overweight,Obesity
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin…
- Trial name
- NCT07550816
- Testing
- ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxin
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Thromboembolism, Bleeding
Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
The optimal medical strategy for prevention of thromboembolic events after bioprosthetic aorta valve replacement (BAVR) remains controversial.
- Trial name
- NCT01452568
- Testing
- Aspirin, Warfarin
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bruises
Patients Preference With Self-Injection: The PRISM Study
The purpose of this study is to determine which short-acting blood thinner (low-molecular-weight heparin [Enoxaparin] or unfractionated heparin) is associated with less discomfort and bruising when given as a subcutaneous (under…
- Trial name
- NCT00253396
- Testing
- Unfractionated heparin, Enoxaparin
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Ischemic Stroke
Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection
Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection.
- Trial name
- NCT00265408
- Testing
- aspirin, warfarin
- Where
- United States
- Sponsor
- University of California, San Diego
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF)
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis
This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital [a tertiary care hospital in Al Ain, UAE].
- Conditions
- End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
- Trial name
- WARD (NCT06606275)
- Testing
- Apixaban, Warfarin
- Where
- United Arab Emirates
- Volunteers
- 67 people
- Sponsor
- Abu Dhabi Health Services Company
Thrombotic Stroke, Atrial Fibrillation and Flutter
ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)
The aim of this study is to evaluate the present status of stroke prevention strategies in patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- RAMSES (NCT02344901)
- Where
- 62 sites in Turkey (Türkiye)
- Volunteers
- 6,273 people
- Sponsor
- Muğla Sıtkı Koçman University
Antiphospholipid Syndrome (APS), Cohort Study
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier…
- Conditions
- Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events
- Trial name
- DOWAPS (NCT06884384)
- Testing
- Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
- Where
- 13 sites in France
- Volunteers
- 310 people
- Sponsor
- Central Hospital, Nancy, France
Healthy
A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin
The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a…
- Trial name
- NCT01133366
- Testing
- warfarin sodium, mipomersen sodium; warfarin sodium
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Venous Thrombosis
Switching Study From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when switching the treatment from warfarin to rivaroxaban.
- Trial name
- NCT01507051
- Testing
- Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Vitamin K (Konakion)
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Cardiopathy, Chagas Disease
Outcomes of an Anticoagulation Clinic in an University Hospital
A clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in Chagas and Non-Chagas disease patients.
- Conditions
- Cardiopathy, Chagas Disease, Hemorrhage, Thrombosis
- Trial name
- NCT01006486
- Testing
- Anticoagulation clinic, Standard anticoagulation care
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Federal University of Minas Gerais
Clotting Disorder
Reinforcement Learning for Warfarin Dosing
This is a clinical study designed to test the hypothesis that a computer model for dosing warfarin is superior to current clinical practice.
- Trial name
- NCT03962400
- Testing
- Reinforcement Learning, Heath Care Provider
- Sponsor
- University of Louisville
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Left Ventricular Thrombus, Acute Myocardial Infarction
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear.
- Trial name
- RESOLVE-AMI (NCT06515730)
- Testing
- Apixaban, Warfarin
- Where
- 16 sites in Sweden
- Volunteers
- 212 people
- Sponsor
- Karolinska Institutet